| SC 13G | 2019-12-13 | Newtyn Management, LLC | CymaBay Therapeutics, Inc. | 3,698,061 | 5.4% | EDGAR |
| SC 13D | 2019-12-12 | ENGINE CAPITAL, L.P. | CymaBay Therapeutics, Inc. | 4,083,460 | 5.9% | EDGAR |
| SC 13G | 2019-08-01 | INTEGRATED CORE STRATEGIES (US) LLC | CymaBay Therapeutics, Inc. | 3,698,225 | 5.4% | EDGAR |
| SC 13G | 2019-06-07 | Point72 Asset Management, L.P. | CymaBay Therapeutics, Inc. | 4,307,900 | 6.3% | EDGAR |
| SC 13G | 2019-03-11 | PERCEPTIVE ADVISORS LLC | CymaBay Therapeutics, Inc. | 4,242,821 | 6.3% | EDGAR |
| SC 13G/A | 2019-02-14 | PERCEPTIVE ADVISORS LLC | CymaBay Therapeutics, Inc. | 2,462,821 | 4.1% | EDGAR |
| SC 13G/A | 2019-02-13 | FMR LLC | CymaBay Therapeutics, Inc. | 547,528 | 0.9% | EDGAR |
| SC 13G/A | 2019-02-13 | ADAGE CAPITAL PARTNERS GP, L.L.C. | CymaBay Therapeutics, Inc. | 2,160,150 | 3.6% | EDGAR |
| SC 13G/A | 2019-02-13 | Foresite Capital Fund III, L.P. | CymaBay Therapeutics, Inc. | 1,587,101 | 2.7% | EDGAR |
| SC 13G/A | 2019-02-13 | BAKER BROS. ADVISORS LP | CymaBay Therapeutics, Inc. | 4,917,700 | 8.3% | EDGAR |
| SC 13G | 2019-02-08 | BlackRock Inc. | CymaBay Therapeutics, Inc. | 5,161,581 | 8.7% | EDGAR |
| SC 13G/A | 2018-06-11 | FMR LLC | CymaBay Therapeutics, Inc. | 3,234,590 | 5.5% | EDGAR |
| SC 13G/A | 2018-02-14 | Abingworth LLP | CymaBay Therapeutics, Inc. | 1,147,077 | 2.6% | EDGAR |
| SC 13G/A | 2018-02-13 | ADAGE CAPITAL PARTNERS GP, L.L.C. | CymaBay Therapeutics, Inc. | 3,279,526 | 7.5% | EDGAR |
| SC 13G/A | 2018-02-13 | Foresite Capital Fund III, L.P. | CymaBay Therapeutics, Inc. | 600,000 | 1.4% | EDGAR |
| SC 13G | 2018-02-13 | BAKER BROS. ADVISORS LP | CymaBay Therapeutics, Inc. | 2,991,775 | 6.8% | EDGAR |
| SC 13G/A | 2018-02-12 | FMR LLC | CymaBay Therapeutics, Inc. | 5,836,913 | 10.5% | EDGAR |
| SC 13G | 2018-02-09 | FMR LLC | CymaBay Therapeutics, Inc. | 2,327,520 | 5.3% | EDGAR |
| SC 13G | 2017-11-14 | PERCEPTIVE ADVISORS LLC | CymaBay Therapeutics, Inc. | 2,685,882 | 6.1% | EDGAR |
| SC 13G | 2017-11-06 | Foresite Capital Fund III, L.P. | CymaBay Therapeutics, Inc. | 600,000 | 1.4% | EDGAR |